Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease

Vascular Medicine (United Kingdom)

Volumn 19, Issue 6, 2014, Pages 473-482

  Olson, Eric ^a   Demopoulos, Laura ^a   Haws, Thomas F ^a   Hu, Erding ^a   Fang, Zixing ^a   Mahar, Kelly M ^a   Qin, Pu ^a   Lepore, John ^a   Bauer, Timothy A ^b   Hiatt, William R ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

6 minute walk test; claudication (see intermittent claudication); exercise performance; GSK1278863; HIF target genes; HIF prolyl hydroxylase inhibitors; peripheral artery disease; subchronic dosing

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; GSK 1278863; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PROLYL HYDROXYLASE INHIBITOR;

6 MINUTE WALK TEST; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLAUDICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXERCISE; FATIGUE; FEMALE; FUNCTION TEST; GASTROCNEMIUS MUSCLE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE BIOPSY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACOKINETICS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; AGED; CLINICAL TRIAL; DRUG EFFECTS; EXERCISE TEST; INTERMITTENT CLAUDICATION; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHYSIOLOGY; QUALITY OF LIFE; SKELETAL MUSCLE; TIME; TREATMENT OUTCOME; VERY ELDERLY; WALKING;

ADULT; AGED; AGED, 80 AND OVER; EXERCISE TEST; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PERIPHERAL ARTERIAL DISEASE; PROLYL-HYDROXYLASE INHIBITORS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 84914098806     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X14557151     Document Type: Article

References (47)

1. Peach G, Griffin M, Jones KG, et al. Diagnosis and management of peripheral arterial disease. BMJ. 2012 ; 345: e5208
2. Capecchi PL, Pasini FL, Cati G, et al. Experimental model of short-time exercise-induced preconditioning in POAD patients. Angiology. 1997 ; 48: 469-480
3. Ke Q, Costa M.. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006 ; 70: 1469-1480
4. Park JW, Chun YS, Kim MS.. Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci. 2004 ; 94: 221-232
5. Takubo K, Nagamatsu G, Kobayashi CI, et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell. 2013 ; 12: 49-61
6. Fukuda R, Zhang H, Kim JW, et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007 ; 129: 111-122
7. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006 ; 3: 187-197
8. Lee FS, Percy MJ.. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011 ; 6: 165-192
9. Salceda S, Caro J.. Hypoxia-inducible factor 1 alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997 ; 272: 22,642-22,647
10. Semenza GL.. Hypoxia-inducible factors in physiology and medicine. Cell. 2012 ; 148: 399-408
11. Cai Z, Zhong H, Bosch-Marce M, et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res. 2008 ; 77: 463-470
12. Eckle T, Kohler D, Lehmann R, et al. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008 ; 118: 166-175
13. Provenzano R, Fadda G, Bernardo M, et al. FG2216, A novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD. Am J Kidney Dis. 2008 ; 51: B80
14. Chang EI, Loh SA, Ceradini DJ, et al. Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation. 2007 ; 116: 2818-2829
15. Van Weel V, Seghers L, de Vries MR, et al. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arterioscler Thromb Vasc Biol. 2007 ; 27: 1426-1432
16. Loinard C, Ginouves A, Vilar J, et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation. 2009 ; 120: 50-59
17. Vigano A, Ripamonti M, De Palma S, et al. Proteins modulation in human skeletal muscle in the early phase of adaptation to hypobaric hypoxia. Proteomics. 2008 ; 8: 4668-4679
18. Bao W, Qin P, Needle S, et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010 ; 56: 147-155
19. Monteiro DP, Britto RR, Lages AC, et al. Heel-rise test in the assessment of individuals with peripheral arterial occlusive disease. Vasc Health Risk Manag. 2013 ; 9: 29-35
20. McDermott MM, Tian L, Liu K, et al. Prognostic value of functional performance for mortality in patients with peripheral artery disease. J Am Coll Cardiol. 2008 ; 51: 1482-1489
21. McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA. 2009 ; 301: 165-174
22. Van Uden CJ, van der Vleuten CJ, Kooloos JG, et al. Gait and calf muscle endurance in patients with chronic venous insufficiency. Clin Rehabil. 2005 ; 19: 339-344
23. Ouma GO, Jonas RA, Usman MH, et al. Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease. Vasc Med. 2012 ; 17: 174-192
24. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003 ; 108: 1933-1938
25. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011 ; 124: 1765-1773
26. Regensteiner JG, Wolfel EE, Brass EP, et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation. 1993 ; 87: 413-421
27. Kemp GJ, Roberts N, Bimson WE, et al. Muscle oxygenation and ATP turnover when blood flow is impaired by vascular disease. Mol Biol Rep. 2002 ; 29: 187-191
28. Kemp GJ.. Mitochondrial dysfunction in chronic ischemia and peripheral vascular disease. Mitochondrion. 2004 ; 4: 629-640
29. Kemp GJ, Roberts N, Bimson WE, et al. Mitochondrial function and oxygen supply in normal and in chronically ischemic muscle: a combined 31P magnetic resonance spectroscopy and near infrared spectroscopy study in vivo. J Vasc Surg. 2001 ; 34: 1103-1110
30. Lundgren F, Zachrisson H, Emery P, et al. Leg exchange of amino acids during exercise in patients with arterial insufficiency. Clin Physiol. 1988 ; 8: 227-241
31. Hammarsten J, Bylund-Fellenius AC, Holm J, et al. Capillary supply and muscle fibre types in patients with intermittent claudication: relationships between morphology and metabolism. Eur J Clin Invest. 1980 ; 10: 301-305
32. Wang H, Hiatt WR, Barstow TJ, et al. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur J Appl Physiol. 1999 ; 80: 22-27
33. Ameln H, Gustafsson T, Sundberg CJ, et al. Physiological activation of hypoxia inducible factor-1 in human skeletal muscle. FASEB J. 2005 ; 19: 1009-1011
34. Fluck M.. Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli. J Exp Biol. 2006 ; 209: 2239-2248
35. Moslehi J, Libby P.. You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes. Circ Res. 2012 ; 110: 1045-1046
36. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008 ; 40: 170-180
37. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 2000 ; 102: 2255-2261
38. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 ; 97: 1114-1123
39. Gardner AW, Poehlman ET.. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 ; 274: 975-980
40. Watson L, Ellis B, Leng GC.. Exercise for intermittent claudication. Cochrane Database Sys Rev. 2008 ; (4). CD000990
41. Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Sys Rev. 2006 ; (2). CD005263
42. Lundby C, Calbet JA, Robach P.. The response of human skeletal muscle tissue to hypoxia. Cell Mol Life Sci. 2009 ; 66: 3615-3623
43. Lundby C, Gassmann M, Pilegaard H.. Regular endurance training reduces the exercise induced HIF-1alpha and HIF-2alpha mRNA expression in human skeletal muscle in normoxic conditions. Eur J Appl Physiol. 2006 ; 96: 363-369
44. Kes P, Bobic I, Reiner Z, et al. [Effect of erythropoietin therapy on serum lipoprotein levels in patients on hemodialysis]. Lijec Vjesn. 2002 ; 124: 146-150
45. Allegra V, Martimbianco L, Vasile A.. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant. 1997 ; 12: 924-932
46. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012 ; 125: 130-139
47. Hamburg NM, Balady GJ.. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011 ; 123: 87-97